Literature DB >> 2660996

Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures.

K K Pun1, L W Chan.   

Abstract

Spinal collapse is a painful complication of osteoporosis. In this study, the analgesic effect of salmon calcitonin, administered intranasally (200 IU per day), was assessed in 18 patients with acute collapse of one to four vertebrae. Pain was evaluated by a descriptive pain scale (ie, Keele's) as well as by the daily consumption of analgesic drugs. When compared with placebo, intranasal salmon calcitonin significantly relieved pain and occasioned a decrease in the consumption of analgesic drugs. No major side effects were reported by the patients under study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660996

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  33 in total

1.  Rheumatology: 15. Osteoporosis.

Authors:  J P Wade
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

Review 2.  Nasal calcitonin.

Authors:  S L Silverman
Journal:  Endocrine       Date:  1997-04       Impact factor: 3.633

Review 3.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 4.  Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials.

Authors:  Jennifer A Knopp; Barry M Diner; Maurice Blitz; George P Lyritis; Brian H Rowe
Journal:  Osteoporos Int       Date:  2004-12-22       Impact factor: 4.507

Review 5.  Use of calcitonin in the treatment of bone pain associated with osteoporosis.

Authors:  C Gennari; D Agnusdei; A Camporeale
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 6.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

7.  Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.

Authors:  Takuo Fujita; Mutsumi Ohue; Mikio Nakajima; Yoshio Fujii; Akimitsu Miyauchi; Yasuyuki Takagi
Journal:  J Bone Miner Metab       Date:  2011-04-01       Impact factor: 2.626

Review 8.  Calcitonin in the treatment of osteoporosis.

Authors:  C Gennari; A Camporeale
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 9.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Calcitonin for prevention and treatment of postmenopausal osteoporosis.

Authors:  J J Body
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.